Evaluation of radioiodine therapy in differentiated thyroid cancer subjects with elevated serum thyroglobulin and negative whole body scan using 131I with emphasize on the thallium scintigraphy in these subgroups

European Review for Medical and Pharmacological Sciences

Volumn 15, Issue 10, 2011, Pages 1215-1221

  Zakani, A ^a   Saghari, M ^b   Eftekhari, M ^a,b   Fard Esfahani, A ^b   Fallahi, B ^b   Esmaili, J ^a   Assadi, Majid ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c BUSHEHR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

131I whole body scan; 201Tl; Differentiated thyroid cancer (DTC); Thyroglobulin (Tg)

Indexed keywords

IODINE 131; RADIOACTIVE IODINE; THALLIUM 201; THYROGLOBULIN;

ADULT; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; FEMALE; FOLLOW UP; HUMAN; MALE; SCINTIGRAPHY; THYROGLOBULIN BLOOD LEVEL; TREATMENT RESPONSE; WHOLE BODY SCINTISCANNING;

ADULT; AGED; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; THALLIUM RADIOISOTOPES; THYROGLOBULIN; THYROID NEOPLASMS; WHOLE-BODY COUNTING;

EID: 82455206132     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. RUGGIERI M, STRANIERO A, PACINI FM, MAIUOLO A, MASCARO A, GENDERINI M. Video-assisted surgery of the thyroid diseases. Eur Rev Med Pharmacol Sci 2003; 7: 91-96.
2. EFTEKHARI M, ASADOLLAHI A, BEIKI D, IZADYAR S, GHOLAMREZANEZHAD A, ASSADI M, FARD-ESFAHANI A, FALLAHI B, TAKAVAR A, SAGHARI M. The long term effect of levothyroxine on bone mineral density in patients with well differentiated thyroid carcinoma after treatment. Hell J Nucl Med 2008; 11: 160-163.
3. 131I whole-body scan after initial treatment of low-risk differentiated thyroid cancer. Thyroid 2004; 14: 301-306.
4. RUGGIERI M, GENDERINI M, GARGIULO P, DEL GRAMMASTRO A, MASCARO A, LUONGO B, PAOLINI A. Surgical treatment of differentiated microcarcinomas of the thyroid. Eur Rev Med Pharmacol Sci 2001; 5: 85-89.
5. BAUDIN E, DO CAO C, CAILLEUX AF, LEBOULLEUX S, TRAVAGLI JP, SCHLUMBERGER M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 2003; 88: 1107-1111.
6. 131I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999; 84: 2291-2302.
7. 131I activities versus untreated patients. J Clin Endocrinol Metab 2001; 86: 4092-4097.
8. FATOURECHI V, HAY ID, JAVEDAN H, WISEMAN GA, MULLAN BP, GORMAN CA. Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer. J Clin Endocrinol Metab 2002; 87: 1521-1526.
9. CAPLAN RH, WICKUS GG, MANSKE BR. Long-term follow-up of a patient with papillary thyroid carcinoma, elevated thyroglobulin levels, and negative imaging studies. Endocr Pract 2005; 11: 43-48.
10. 131I whole-body scans and elevated thyroglobulin levels: a possible course]. Rev Esp Med Nucl 2007; 26: 138-145.
11. CHAO M. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan. Clin Oncol (R Coll Radiol) 2010; 22: 438-447.
12. SHERMAN SI. Thyroid carcinoma. Lancet 2003; 361(9356): 501-511.
13. MACAPINLAC HA. Clinical usefulness of FDG PET in differentiated thyroid cancer. J Nucl Med 2001; 42: 77-78.
14. 131I whole-body scanning results? J Nucl Med 2005; 46: 1164-1170.
15. FATOURECHI V, HAY ID. Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance. Semin Nucl Med 2000; 30: 107-114.
16. PINEDA JD, LEE T, AN K, REYNOLDS JC, ROBBINS J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995; 80: 1488-1492.
17. 131I whole-body scan: comparative study. Clin Endocrinol (Oxf) 2003; 58: 421-427.
18. VAN TOL KM, JAGER PL, DE VRIES EG, PIERS DA, BOEZEN HM, SLUITER WJ, DULLAART RP, LINKS TP. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. Eur J Endocrinol 2003; 148: 589-596.
19. PACINI F, LIPPI F, FORMICA N, ELISEI R, ANELLI S, CECCARELLI C, PINCHERA A. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 1987; 28: 1888-1891.
20. SAGHARI M, GHOLAMREZANEZHAD A, MIRPOUR S, EFTEKHARI M, TAKAVAR A, FARD-ESFAHANI A, FALLAHI B, BEIKI D. Efficacy of radioiodine therapy in the treatment of elevated serum thyroglobulin in patients with differentiated thyroid carcinoma and negative whole-body iodine scan. Nucl Med Commun 2006; 27: 567-572.
21. MAZZAFERRI EL, KLOOS RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86: 1447-1463.
22. KIM WG, RYU JS, KIM EY, LEE JH, BAEK JH, YOON JH, HONG SJ, KIM ES, KIM TY, KIM WB, SHONG YK. Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan. J Clin Endocrinol Metab 2010; 95: 1169-1173.
23. 131I negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma: what is being treated? Thyroid 1997; 7: 669-672.
24. ZOLLER M, KOHLFUERST S, IGERC I, KRESNIK E, GALLOWITSCH HJ, GOMEZ I, LIND P. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality? Eur J Nucl Med Mol Imaging 2007; 34: 487-495.
25. DONG MJ, LIU ZF, ZHAO K, RUAN LX, WANG GL, YANG SY, SUN F, LUO XG. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis. Nucl Med Commun 2009; 30: 639-650.
26. CHIN BB, PATEL P, COHADE C, EWERTZ M, WAHL R, LADENSON P. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2004; 89: 91-95.
27. COOPER DS, DOHERTY GM, HAUGEN BR, KLOOS RT, LEE SL, MANDEL SJ, MAZZAFERRI EL, MCIVER B, PACINI F, SCHLUMBERGER M, SHERMAN SI, STEWARD DL, TUTTLE RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.
28. BRENDEL AJ, GUYOT M, JEANDOT R, LEFORT G, MANCIET G. Thallium-201 imaging in the follow-up of differentiated thyroid carcinoma. J Nucl Med 1988; 29: 1515-1520.
29. DADPARVAR S, CHEVRES A, TULCHINSKY M, KRISHNA-BADRINATH L, KHAN AS, SLIZOFSKI WJ. Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation. Eur J Nucl Med 1995; 22: 1330-1338.
30. CARRIL JM, QUIRCE R, SERRANO J, BANZO I, JIMENEZ-BONILLA JF, TABUENCA O, BARQUIN RG. Total-body scintigraphy with thallium-201 and iodine-131 in the follow-up of differentiated thyroid cancer. J Nucl Med 1997; 38: 686-692.
31. 201Tl, and Tc-99m-MIBI scintigraphy for metastatic differentiated thyroid carcinoma after total thyroidectomy. Acta Med Okayama 2005; 59: 99-107.